Nkọwapụta adịghị ọcha Peptide: Ihe Mere Otu Atọm ji agbanwe Biology

Ihe Oxygen-na-Nitrogen Swap Na-agbanwe N'ezie

Iji ester dochie amide bụ obere ndezi na mpempe akwụkwọ yana nke buru ibu na oghere akụkụ atọ.. Nitrogen amide bụ onye na-enye onyinye hydrogen; ester oxygen abụghị. Gbanwee nitrogen maka oxygen na njikọ ahụ na-efunahụ onye nyere onyinye ahụ, na-ebelata carbonyl dị ka onye na-anabata hydrogen-bond, na-ebelata resonance amide na peptide-bond dipole, ma na-ahapụ ọkpụkpụ azụ ka ọ tụgharịa ka ọ bụrụ ọdịdị nke amide gaara ekpochapụ. Gbaa edit ahụ n'ụzọ ọzọ, oxygen na nitrogen, na nke ọ bụla n'ime mmetụta ndị ahụ na-atụgharị: njikọ ahụ na-enweta onye na-enye onyinye, na-ewusi onye nabatara ike, ma na-aghọkwu atụmatụ ma na-esi ike karị (Amide bond bioisosteres nyochaa, 2020). Otu peptide nke njikọ amide na-aghọ ester bụ depsipeptide, na ọ bụ ihe atụ kasị ọcha nke ihe mgbanwe otu atọm a na-eme.

Ihe mgbochi ntụgharị na-akọwapụta ọdịiche ahụ. N'otu akwụkwọ nkuzi nkuzi steeti Michigan, ihe mgbochi maka njikọ NH₂–CHO na formamide agwụla 18 kcal/mol, na ihe mgbochi CH₃O-CHO na methyl formate bụ 12-13 kcal/mol. (Reusch, Akwụkwọ mmụta Virtual nke Organic Chemistry). Gụọ akụkụ n'akụkụ, nke ahụ bụ 5-6 kcal / mol dị iche n'otú ọkpụkpụ azụ si eguzogide ntụgharị.

Oghere ahụ dabara adaba, ọ bụghị ịchọ mma. Njikọ nke na-atụgharị n'ụdị n'efu na-eme ka amide enweghị ike iru, na nsonaazụ nyocha ọ bụla nke mgbada na-eketa ọdịiche ahụ.

Ihe kpatara otu Atọm Swap nwere ike degharịa omume ndu

Otu ndezi otu atom abụghị obere mgbanwe mgbe atom na-anọdụ n'ime ụlọ ọgwụ. Ọ na-edegharị njikọ nke hydrogen na netwọk eletriki nke molekul, na bayoloji na-esote.

Ihe edeputara nke ọma bụ swap ester-to-amide n'otu ọnọdụ. Na ọrụ e bipụtara na Akwụkwọ akụkọ European of Pharmacology n'ime 2016, na otu nnọchi gbanwere ester precursor SH-053-2'F-R-CH3 n'ime MP-III-022 wee gbanwee nhọrọ nhọrọ, arụmọrụ na omume kinetic na α5-subunit nwere GABA-A ndị nnata., na-adabere na dose ike scaling si 138% ka 314% site na 1-10 mg / kg (Akwụkwọ akụkọ European of Pharmacology, 2016). Nhọrọ nhọrọ, arụmọrụ na kinetics niile kpaliri n'ihi na otu atọm kwagara.

Otu ndezi nwere ike ịkwaga n'ụzọ ọzọ. Nlebanya nke nnọchi bioisosteric na imewe ọgwụ mgbochi HIV, bipụtara na 2020, na-edekọ mgbanwe ester-to-secondary-amide nke belatara pụtara ike site na 1.26 nkeji pCheEMBL gafee 14 dakọtara ụzọ abụọ (Ndochi bioisosteric dị ka ngwa ọrụ na imepụta ọgwụ mgbochi HIV, 2020). Ihe dị ka okpukpu iri na abụọ, site na otu atọm.

Ụkpụrụ dị n'azụ nsonaazụ abụọ ahụ: Ndochi bioisosteric na-arụ ọrụ naanị mgbe pharmacophore dị ndụ. A na-anabata swap mgbe atom na-abụghị akụkụ nke pharmacophore, na ọ na-ewepụ ọrụ mgbe ọ na-agbanwe onye na-enye onyinye ma ọ bụ nnabata hydrogen chọrọ, pKa, a conformation ma ọ bụ eletrọnịkị nkesa. Enwere ike ịnabata otu mgbanwe ahụ n'otu klaasị ebumnuche wee daa na nke ọzọ.

Ma isi mmalite usoro sitere na 2016 na 2020. A na-akpọ ha ebe a dị ka usoro, ọ bụghị dị ka nkwupụta banyere ọnọdụ nke ubi ugbu a.

Ihe kpatara ịdị ọcha Chromatographic abụghị nsonaazụ njirimara

Ọnụ ọgụgụ ịdị ọcha nke HPLC na-agbanwe agbanwe na-akọwa etu ihe siri pụta dị ka otu ọnụ ọgụgụ kacha elu n'okpuru otu ọnọdụ chromatographic.. Ọ naghị akọwa ihe ihe ahụ bụ. Otu ọnụ ọgụgụ dị ọcha abụghị nsonaazụ njirimara, and treating it as one is where peptide impurity profiling most often goes wrong.

The mechanism is straightforward. RP-HPLC separates on chromatographic behaviour and detects on UV response, so a structurally related or isobaric impurity that co-elutes leaves the chromatogram looking unchanged. Sequence isomers, racemized, deamidated and isomerized forms can share mass or UV signal with the target (Nyocha HPLC na nhicha nke Peptides, PMC book chapter, emechiri emechi). Single-wavelength UV adds a second blind spot: at the 214–220 nm peptide-bond wavelength it reports a shared backbone signal rather than a compound-specific one, and UV-silent species do not appear at all.

Mass accuracy is what separates the two questions, and the budget is tighter than most people assume. An oxygen-to-nitrogen substitution shifts exact mass by roughly 0.0364 Na, nke na-anọdụ n'ime njehie okirikiri nke echiche ọnụ ọgụgụ-ọnụ ọgụgụ ma nwee ike ịgụhie ya dị ka usoro a chọrọ.

Ntugharị igodo： A 0.0364 Ngbanwe ahụ pere mpe nke na ọrụ n'ọnụ ọgụgụ agaghị egosipụta ya. Idozi ya chọrọ uka ziri ezi, ọ bụghị pasent nke ịdị ọcha.

Ego ole na-edozi ike na-ewe dabere na ngwá ọrụ ahụ. Thermo Fisher na-akọ Orbitrap Exploris 240 na 15,000 ka 240,000 FWHM na m/z 200 na sub-ppm uka izi ezi, edobere maka ọdịiche isobaric (Thermo Fisher Sayensị), isi iyi onye na-ere ere, ya mere gụọ nkọwapụta dị ka uko ụlọ karịa nsonaazụ oge niile. Mmiri na-akọwa ngwa QTOF na ppm ole na ole, a TOF na roughly 5,000 na-edozi ike na-ekewa ọnụ ọnụ ọnụ nke a na-atụ n'okpuru 5 ppm, na ngwa kacha zie ezi-oke na 10 ppm ma ọ bụ karịa (Mmiri Mass Spectrometry Primer), nakwa ihe na-ere ahịa. Isi ihe bara uru na-ejide ụzọ ọ bụla: mmefu ego ppm na-agbatị ka molekul na-ebuwanye ibu, ya mere usoro akwadoro na peptide dị mkpụmkpụ anaghị ebufe ozugbo na usoro 40 fọdụrụnụ.

Nkọwapụta adịghị ọcha Peptide: Ihe Nkịtị chọrọ n'ezie

Nkọwapụta adịghị ọcha peptide na-amalite n'otu ajụjụ: nke ọnụ ụzọ na-emetụta molekul gị? N'ihi na a kacha kwa ụbọchị dose nke 2 g / ụbọchị ma ọ bụ obere, ICH Q3A izugbe(R2)/Q3B(R2) framework setịpụ akụkọ na 0.05%, njirimara na 0.10% ma ọ bụ 1.0 mg / ụbọchị (nke ọ bụla dị ala), na iru eru na 0.15% ma ọ bụ 1.0 mg / ụbọchị (nke ọ bụla dị ala). N'elu 2 g/ụbọchị, ha atọ ga-adaba 0.03%, 0.05%, na 0.05% n'otu n'otu (oke mkpesa na iru eru, I Q3A(R2), 2006).

A naghị achịkwa peptides sịntetik site na nọmba ndị ahụ. I Q6B, Usoro nkọwapụta maka protein na polypeptides, hoo haa anaghị ekpuchi peptides sịntetik na ụdị EMA, yabụ ntuziaka peptide-kpọmkwem FDA na EMA na-emetụta kama (peptide-kpọmkwem threshold framework, I Q6B, 1999). Ntuzi aka ahụ chọrọ nkọwapụta na njirisi nnabata ka ọ bụrụ nke ziri ezi na sayensị, na-elebara anya nke ọma na profaịlụ adịghị ọcha, and notes a biological assay is generally not expected for release of synthetic peptides. Under the EMA/Ph. Euro. peptide framework, the working values are report above 0.1%, mata n'elu 0.5%, ma tozuo oke 1.0%.

Otu caveat: the primary PDF tables could not be opened this round, and these figures trace to a single upstream source. Treat them as the framework to verify against the current guideline text, not as a quoted table.

Nkwenye ihe owuwu: Usoro nke Orthogonal usoro, Na-adịghị Stacking Ha

Structural confirmation of peptides is a sequence, not a pile of certificates. Primary identity comes first: HRMS or LC-MS/MS measured against the calculated mass and isotope pattern. Only then does orthogonal confirmation follow, using amino acid analysis, maapụ peptide, na, where isomerism or conformation matters, NMR and sometimes ion mobility. At least two orthogonal methods are recommended for identity (Na-eji atụmatụ dabere na orthogonal mass spectrometry, 2020).

Na omume kwa-nza, ịdị ọcha chromatographic na nlele profaịlụ na-ebu ụzọ tuo ọkọlọtọ, mgbe ahụ emebibeghị oke, wee nkwenye usoro, mgbe ahụ imezigharị megide mgbanwe ndị a tụrụ anya na profaịlụ adịghị ọcha. Usoro ahụ dị mkpa n'ihi na nzọụkwụ ọ bụla na-ebelata ihe nke ọzọ ga-edozi.

Ihe ngwungwu nkwado ahụ nwere ajụjụ a na-ajụ. N'okpuru I Q2(R2) Nkwado nke usoro nyocha (2023, mmezi njehie 2025), ule njirimara na-achọkarị nkọwapụta na nhọrọ naanị. Nnwale adịghị ọcha chọrọ nkọwapụta, izi ezi, nkenke, oke, na-abụkarị linearity, na nkenke nyochara na opekata mpe 9 mkpebi n'ofe a na-akọ akụkọ, ma ọ bụ 6 na 100% nke ule ịta.

Mara ihe usoro ọ bụla enweghị ike ime. LC-MS na-enye uka na, na MS/MS, saịtị mgbanwe nke gbawara agbawa, mana ọ naghị ekewapụta ụfọdụ isomers ma ọ bụ kwado stereochemistry. Nyocha Amino acid na-akwado ihe mejupụtara ya, ọ bụghị usoro n'usoro. Oghere ahụ bụ ya mere usoro nyocha nke orthogonal maka peptides ji bụrụ usoro kama ikpokọta ya.

Ịmekọrịta Data Analytical na Bioactivity

Mgbe ọtụtụ gafere nkọwapụta ịdị ọcha chromatographic mana nsonaazụ nyocha adabaghị ike ma ọ bụ nhọrọ nhọrọ, na-emeso ndịiche dị ka nchoputa. Uru ịdị ọcha Peptides sịntetik na-akọwa ole ihe onwunwe dị, ọ bụghị nke molekul ọ bụ, ya mere nyocha nke na-arụ ọrụ nke ọma na-akọkarị eziokwu nhazi nke chromatogram enweghị ike idozi.

Usoro ọgwụgwọ na-arụ ọrụ n'otu ụzọ ahụ, site na amaghi ama azụ na nhazi:

1. Wepụ ihe metụtara ya site na ụdị nkewa orthogonal, ya mere a na-eji usoro dị iche na nke na-ekwe ka ọ gafee.

2. Mepụta saịtị mgbanwe site na nkewa MS/MS, na-eji usoro mpempe akwụkwọ na-etinye ngbanwe nke oke n'otu ihe fọdụrụ.

3. Kwado ọkpụkpụ azụ n'onwe ya site na nyocha amino acid ma ọ bụ nkewa peptide, nke na-akọ ihe mejupụtara karịa ka emebibeghị oke.

4. Megharịa nyocha bioactivity megide usoro akwadoro, yabụ nsonaazụ ike ma ọ bụ selectivity ugbu a jikọtara ya na molekul amaara.

Nzọụkwụ ikpeazụ ahụ bụ ihe na-eme ka usoro ahụ baa uru. Ruo mgbe a kwadoro nhazi ahụ, Nnwale ahụ na-atụle ngwakọta na-amaghị ama, na nkọwa bioactivity peptide ọ bụla ewepụtara na ya bụ nwa oge.

Ntugharị igodo: Mgbe chemistry na data assay ekwekọrịtaghị, ọbụghịkwa nsonaazụ a na-atụfu. Chromatogram na-akọwa ihe kewapụrụ; nyocha na-akọwa ihe ihe na-eme. Ọdịiche dị n'etiti ha bụ echiche adịghị ọcha iji nwalee.

Maka otu ndị na-agba ọsọ peptide gbanwetụrụ n'akụkụ nnwale nke ndu, MOL Mgbanwe na-akwado njikọ agbakwunyere, mgbanwe na QC, nke na-edobe data nhazi na ọrụ n'otu ndekọ nza.

Echiche ezighi ezi na ebe ha na-eri gị

Echiche anọ na-ebute ọtụtụ nsogbu na nyocha peptide, na nke ọ bụla nwere kpọmkwem usoro na-edozi ya.

"Otu pasent dị ọcha bụ mkpebi dị mma." Ọ bụ nsonaazụ nkewa. A 98% Mpaghara HPLC na-agwa gị ego ole gbagoro dị ka isi kacha elu n'okpuru otu ọnọdụ. Ọ dịghị ihe ọ na-ekwu banyere ma ọnụ ọgụgụ kasị elu ahụ ọ̀ bụ molekul ziri ezi. Ịdị ọcha na njirimara bụ ajụjụ dị iche iche chọrọ azịza dị iche iche.

“Mass confirmation establishes structure.” Mass spectrometry establishes composition: the summed formula, and therefore the expected molecular weight. It does not establish sequence order or stereochemistry. Two peptides with identical mass can differ in which residue sits where, or in the configuration at a single centre. Sequencing methods, not a mass figure, close that gap.

“A biological assay is always required for release.” Under the EMA guideline on synthetic peptides, a biological assay is generally not expected as part of routine release testing. Where the record stops: that is a regulatory expectation, not a statement that bioactivity is irrelevant. If your specification claims a biological effect, you still need the data behind it. Mmepụta Peptide

“A single-atom edit is a minor change.” Dị ka akụkụ ndị mbụ si kwuo, Ngbanwe oxygen-na-nitrogen nwere ike gbanwee ike site n'usoro nke ịdị ukwuu ma ọ bụ ntụgharị nhọrọ.. Chemistry dị obere; bayoloji anaghị eso.

Gụọ dị ka ndepụta nlele, Ndozi anọ ahụ na-esetịpụ otu ajụjụ gaa n'otu usoro: nkewa na ịdị ọcha, usoro na nhazi, yana nyocha akọwapụtara maka nkwupụta ọrụ ọ bụla.

Na-amalite: Usoro nlele nke ngafe mbụ

Malite na akwụkwọ ị nweburu. Wepụ ịdị ọcha chromatographic nke nza dị ugbu a, data nkwenye nke oke na usoro, wee jụọ otu ajụjụ nke setịpụ ahụ: njirimara na-adabere na ihe karịrị otu usoro orthogonal, ma ọ bụ nkwubi okwu ahụ ọ dabere na otu chromatogram?

Ọ bụrụ na ọ dabere na otu usoro, ị nwere oghere mbụ gị, na nke ọzọ nke usoro bụ n'ibu.

Nke abụọ, mapụ klas adịghị ọcha aha nke ọ bụla n'usoro na-achọpụta ya. Usoro ihichapụ, ngwaahịa oxidation, isomerization, nchebe na-ezughị ezu na mgbaghara nke ọ bụla nwere usoro na-ejide ha, na klas na-enweghị usoro e kenyere bụ ihe ize ndụ na-enweghị atụ karịa nke dị ala. Tuo ya ọkọlọtọ wee gawa n'ihu.

Nke atọ, mekọrịta profaịlụ adịghị ọcha megide mgbanwe a na-atụ anya ya na bioactivity. Mgbe profaịlụ na nyocha ekwenyeghị, were mismatch dị ka ajụjụ nhazi tupu ewere ya dị ka nsogbu nyocha. Ihe owuwu bụ nkọwa yikarịrị, ma ọ bụ nke dị ọnụ ala iji lelee.

Usoro ahụ na-ewe otu ehihie wee gwa gị ma data ị jide ezuola mkpebi ị na-achọ ime. Ebe ọ na-adịghị, ụzọ kacha ọsọ na-aga n'ihu bụ mkparịta ụka gbasara ihe ngwugwu nyocha ọkwa ọkwa ga-emechi oghere ahụ.

Ajụjụ a na-ajụkarị

Kedu ihe bụ depsipeptide?

Depsipeptide bụ peptide nke njikọ amide na-aghọ ester. Usoro agbanweghị, ma opekata mpe, njikọ azụ azụ na-ebu ndị na-enye onyinye hydrogen ole na ole, nke zuru oke iji gbanwee mpịachi na ntinye aka nnabata. Ọ bụ ya mere a na-eji depsipeptides dị ka klaasị nhazi dị iche kama ịbụ ụdị peptide..

Ịdị ọcha HPLC ọ na-egosi na m nwere usoro a chọrọ?

Mba. Otu ọnụ ọgụgụ dị ọcha abụghị nsonaazụ njirimara. Reverse-phase HPLC kewapụrụ site na hydrophobicity, Ya mere, usoro dị iche iche ma ọ bụ ọkpụkpụ azụ azụ O →N nwere ike imekọrịta ihe na ebumnuche ma ka na-ejikọta dị ka otu. 98% elu. Ịdị ọcha na njirimara bụ nha dị iche iche.

Ego ole ka oke ngbanwe na-agbanwe na O→N, na ihe ngwọta ike na-achọ?

Mgbanwe ahụ na-agbanwe ọkpụkpụ azụ site na a 0.0364 Da uka shift, obere nke ọma na ngwa ọnụ ọgụgụ agaghị ekewapụ ya na usoro a chọrọ. Idozi ya chọrọ nleba anya nke ọma nke ukwuu, na nnukwu peptides isotope envelopu overlap na-eme ka ọdịiche ahụ sie ike.

Bụ nyocha ndu nke achọrọ maka mwepụta peptide sịntetik?

Maka ọtụtụ peptides sịntetik, A naghị atụ anya nyocha nke ndu. Nnwale mwepụta dabere na njirimara, ịdị ọcha, na ọdịnaya, nwere njiri mara bioactivity edobere maka ngwaahịa nke usoro ha na-akọwapụtaghị nke ọma site na nhazi. Ebe usoro gbanwere ma ọ bụ peptidimetic metụtara, dee mkpebi ahụ kama iche ya.

Kedu ụzọ orthogonal achọrọ maka njirimara na nyocha adịghị ọcha?

Ọrụ njirimara na adịghị ọcha na-akpọ maka nkwenye orthogonal, n'usoro. Mass spectrometry na-eguzobe oke molekụla na, na nkewa, usoro. Profaịlụ adịghị ọcha wee chọọ usoro nkewa nwere nhọrọ dị iche iche site na nyocha ntọhapụ, ya mere, a na-edozi ụdị nke na-ejikọta ọnụ karịa ka akwadoro ugboro abụọ site n'otu usoro ahụ. Iji ụzọ nyocha orthogonal maka peptides pụtara ijikọ usoro na-ada n'ụzọ dị iche iche, ọ bụghị ikpokọta ngwa na-ekekọrịta otu ntụpọ.

Kedu ka ọnụ ụzọ ICH Q3A siri dị iche na peptide-kpọmkwem EMA framework?

ICH Q3A na-edobe ntozu na ụzọ njirimara site na dose kwa ụbọchị maka obere ọgwụ ọgwụ., ebe peptide akọwapụtara nke ọma na-emetụta mkpesa na oke iru eru dabara na peptides., ihe ndị metụtara ya na-adịkarị iche na nne na nna site na otu ihe fọdụrụ. Itinye tebụl obere molecule ahụ ozugbo na peptide nwere ike ịtọ ọnụ ụzọ nke na-agaghị ekwe omume izute ma ọ bụ nke na-adịghị mma ka ọ bụrụ ihe bara uru.. Gosipụta usoro na-achịkwa ngwaahịa gị tupu i dozi nkọwapụta.

Mmechi

Mgbanwe ọkpụkpụ azụ nke otu atọ bụ mgbanwe ndu, na ịdị ọcha, njirimara na bioactivity bụ ajụjụ atọ dị iche iche chọrọ ahịrị akaebe atọ dị iche iche. Mgbanwe ikuku oxygen-to-nitrogen na-akpali onye na-enye onyinye hydrogen na onye na-anabata ya, na otu ndezi ahụ nwere ike ịgbanwe ka otu molekul si etinye ebumnuche ya. Ọnụ ọgụgụ ịdị ọcha chromatographic na-aza naanị ajụjụ mbụ. Nkwenye ihe owuwu nke peptides site na usoro orthogonal, wee mezie data kemistri ahụ megide nsonaazụ nyocha, bụ ihe na-emechi abụọ ndị ọzọ.

Oghere ajụjụ atọ ahụ bụ ọkọlọtọ kacha nta a ga-echebe maka ịkọwapụta adịghị ọcha peptide, na ọ bụ ebe a QC usoro ma jide n'aka inyocha ma ọ bụ na-adịghị. Atụmanya usoro iwu maka njiri mara peptide na-esiwanye ike kama ịtọpụ ya, na usoro nrụzigharị ọrụ bụ ebe ọtụtụ mmemme ka na-ebu nnukwu oghere ha. Ọ bụrụ na ị na-atụle ma mgbanwe ahụ ọ bara uru ịme, azịza ziri ezi bụ na ọnụ ahịa na-anọdụ n'ọrụ usoro, ọ bụghị na mkpebi.

Mgbanwe MOL nwere mmasị azụmahịa na ụkpụrụ ịdịmma peptide ma na-enye njikọ omenala na ọrụ nyocha nyocha. Ọ bụrụ na ịchọrọ echiche nke abụọ na panel gị ugbu a, gwa ndị otu nka nka gbasara usoro gị na ajụjụ ndị ị chọrọ data ịza.